Catalyst Pharma Files 8-K on Other Events and Exhibits

Ticker: CPRX · Form: 8-K · Filed: 2024-02-21T00:00:00.000Z

Sentiment: neutral

Topics: 8-K filing, corporate-disclosure, other-events

TL;DR

**Catalyst Pharma just dropped an 8-K for 'Other Events' and 'Financials', so keep an eye out for what's next!**

AI Summary

CATALYST PHARMACEUTICALS, INC. filed an 8-K on February 21, 2024, reporting 'Other Events' and 'Financial Statements and Exhibits'. The filing indicates a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The company, based in Coral Gables, Florida, with IRS Employer Identification No. 76-0837053, has a Commission File Number 001-33057.

Why It Matters

This filing signals that Catalyst Pharmaceuticals has an event or information deemed significant enough to warrant immediate disclosure to investors, potentially impacting market perception or future operations.

Risk Assessment

Risk Level: low — The 8-K filing itself is a standard disclosure and does not inherently indicate high risk without further details on the 'Other Events'.

Key Players & Entities

FAQ

What is the purpose of this 8-K filing by Catalyst Pharmaceuticals, Inc.?

The 8-K filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, specifically reporting 'Other Events' and 'Financial Statements and Exhibits'.

When was this 8-K report filed?

The Date of Report (Date of Earliest Event Reported) is February 21, 2024.

What is the Commission File Number for Catalyst Pharmaceuticals, Inc.?

The Commission File Number for Catalyst Pharmaceuticals, Inc. is 001-33057.

Where is Catalyst Pharmaceuticals, Inc.'s principal executive office located?

The principal executive office of Catalyst Pharmaceuticals, Inc. is located at 355 Alhambra Circle, Suite 801, Coral Gables, Florida 33134.

What is the IRS Employer Identification Number for Catalyst Pharmaceuticals, Inc.?

The I.R.S. Employer Identification No. for Catalyst Pharmaceuticals, Inc. is 76-0837053.

From the Filing

0001193125-24-041520.txt : 20240221 0001193125-24-041520.hdr.sgml : 20240221 20240221163410 ACCESSION NUMBER: 0001193125-24-041520 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240221 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240221 DATE AS OF CHANGE: 20240221 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CATALYST PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001369568 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33057 FILM NUMBER: 24660224 BUSINESS ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 BUSINESS PHONE: (305) 529-2522 MAIL ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 FORMER COMPANY: FORMER CONFORMED NAME: CATALYST PHARMACEUTICAL PARTNERS, INC. DATE OF NAME CHANGE: 20110215 FORMER COMPANY: FORMER CONFORMED NAME: Catalyst Pharmaceutical Partners, Inc. DATE OF NAME CHANGE: 20060719 8-K 1 d706892d8k.htm 8-K 8-K NASDAQ false 0001369568 0001369568 2024-02-21 2024-02-21     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 21, 2024     CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter)       Delaware   001-33057   76-0837053 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   355 Alhambra Circle   Suite 801   Coral Gables ,  Florida   33134 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code: (305) 420-3200 Not Applicable Former Name or Former address, if changed since last report     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of Each Class   Name of Exchange on Which Registered   Ticker Symbol Common Stock, par value $0.001 per share   NASDAQ Capital Market   CPRX Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company  ☐       If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 8.01 Other Events On February 21, 2024, the Company issued a press release announcing that the peer-reviewed journal Neurology has published Santhera Pharmaceutical’s (“ Santhera ”) study titled “Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystroph

View on Read The Filing